Clinical Trial Update: Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating the PD-1 inhibitor tislelizumab in combination with nab-paclitaxel for upper tract urothelial carcinoma, currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: RECRUITING